Pro Medicus Limited (ASX:PME): FY26 Earnings, Imaging Contracts and Product Expansion

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Pro Medicus Limited (ASX:PME): FY26 Earnings, Imaging Contracts and Product Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Pro Medicus (ASX:PME) reported FY26 revenue of AUD 261.7 million, up 22.9%.
FY26 underlying net profit after tax increased 24.1% to AUD 144.7 million.
The company reported ten new contracts worth at least AUD 407 million during FY26.
Cash and other financial assets reached AUD 252.3 million at 30 June 2026.

Pro Medicus Limited (ASX:PME) develops medical imaging software for hospitals, radiology groups and other healthcare organisations, including the Visage 7 enterprise imaging platform. On 22 October 2026, Pro Medicus (ASX:PME) was quoted at AUD 194.11, up 5.02% for the trading session. Its latest FY26 results, announced in August, outlined higher software revenue, new imaging contracts and expanded products. The share-price change is stated as market information rather than attributed to those earlier announcements.

Company Business

The company provides radiology information systems, picture archiving and communication software, image visualisation and related services. Its Visage Imaging operation develops the Visage 7 platform, which enables clinicians to access diagnostic imaging and supports installations in hospital networks. Pro Medicus maintains corporate operations in Melbourne, research and development operations in Berlin and a United States presence in San Diego.

Pro Medicus (ASX:PME) operates across Australia, North America and Europe. Its offerings include enterprise imaging, digital pathology and artificial intelligence-related functionality. Revenue can arise from implementation activity, customer usage and contracted software services, making deployment schedules and client imaging volumes relevant to subsequent reporting periods.

Recent Development

In August 2026, Pro Medicus (ASX:PME) reported signing ten new contracts with minimum aggregate value of AUD 407 million during FY26. The company also renewed six of six contracts, worth AUD 141 million collectively, on five-year terms. These contract values are contractual amounts over their respective terms, rather than revenue recognised immediately in FY26.

The FY26 announcement also identified launches involving digital pathology and AI-optimised reporting. Management reported that the Trinity implementation was largely complete, positioning that installation to contribute across FY27. Separately, an August 2026 ASX announcement detailed a seven-year, AUD 25 million contract with Valley Health. Delivery timing, onboarding and contractual usage arrangements remain relevant to the recognition of revenue.

Financial Performance and Sector Context

For the year ended 30 June 2026, Pro Medicus (ASX:PME) generated revenue from ordinary activities of AUD 261.7 million, an increase of 22.9%. Underlying earnings before interest and tax were AUD 196.1 million, up 24.4%, with the disclosed EBIT margin reaching 74.9%, 90 basis points higher. Underlying profit after tax grew 24.1% to AUD 144.7 million.

Reported net profit after tax was AUD 265.3 million, up 130.3%. This figure differs substantially from underlying earnings because reported results include financial asset fair-value movements. The distinction matters when comparing operating software performance with statutory profit. On a constant-currency basis, the company reported underlying revenue of AUD 273.5 million, an increase of 28.4%, and underlying net profit after tax of AUD 154.5 million, up 32.5%.

At year-end, cash and other financial assets stood at AUD 252.3 million, up 19.7%, and the company described itself as debt-free. The board declared a fully franked final dividend of AUD 0.37 per share, bringing total FY26 dividends to AUD 0.69, up 25.5%. The wider healthcare software market is affected by hospital procurement processes, clinical workflows, interoperability requirements and privacy obligations.

Risks to Consider

Pro Medicus (ASX:PME) faces implementation and contract-timing risks, particularly when large healthcare systems require staged deployments. Changes in customer imaging volumes can influence usage-linked revenue. Cybersecurity, patient information controls and clinical software regulation introduce compliance obligations. Its international footprint also exposes reported Australian-dollar earnings to currency movements. Fair-value movements on financial investments can create volatility in statutory profit without necessarily indicating comparable changes in software operations.

What to Watch Next

Relevant FY27 monitoring points include the contribution from the Trinity deployment, timing of other contract implementations, customer usage, renewal activity and adoption of digital pathology and AI-enabled reporting. Subsequent financial updates from Pro Medicus (ASX:PME) can clarify the relationship between contracted business, recognised revenue, underlying profitability and reported earnings. Updates on the deployment of the Valley Health contract will also provide operational context.

Key Insights

FY26 results show higher revenue and underlying earnings, a larger cash and financial-assets balance and additional contracted imaging work. Reported profit was materially affected by fair-value accounting movements. For Pro Medicus (ASX:PME), implementation milestones, recurring usage, foreign-exchange effects and the difference between statutory and underlying results remain central measures for tracking the business.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.